The association of CCRL2 expression with patient prognosis may be due to its stimulation of AML cell proliferation and its role in increasing DNA methylation, leading to resistance of secondary AML cells to azacitidine [139]. This evidence concerns the gene CCRL2 and acute myeloid leukemia.